Overview
Introduction
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. Currently, the newer targeted biologic therapies against specific molecules involved in the pathogenesis of RA reduce side-effects, but cheaper traditional therapies are still used in the majority of patients. DMARDs are a rapidly changing growth area of the RA market showing high innovation and competition.
Scope
- Detailed pipeline analysis for key products in a specific RA indication, plus drug sales forecasts to 201
- Overview of patient potential, segmentation by indication and unmet needs in RA across the seven major markets
- Benchmarking of key clinical and company attractiveness of the late-Phase pipeline products
- Detailed clinical trial information and opinion from key thought leaders
Report Highlights
If biologic products continue their exponential uptake the market could reach over US$11 billion by 2014. However, this would put an incredible strain on the financial resources of the key markets, as most growth is driven by high biologic pricing and it is likely that restrictions will be put in place to reduce the cost to payers.
Competition will be fierce between the next DMARDs to be launched, Rituxan/MabThera (rituximab) and Orencia (abatacept). Rituximabs promising dosing and use in cancer indications gives it an advantage over abatacepts novel co-stimulatory modulator. Both will initially be competing for anti-TNF failure patients.
The Roche, Biogen Idec and Genentech partnership looks set to dominate future biologic treatments in RA. Roches financial clout and Japanese partnership with Chugai compliments Biogen Idecs immunology innovation and Genentechs protein-based specialist knowledge to place the products from this group at an immediate advantage.
Reasons to Purchase
- Understand why pricing restraint is necessary for the continued exponential uptake and commercial growth of the biologic DMARDs
- Quantify the future size and potential of the market for novel treatments in the RA indication in each of the seven major markets
- Use analysis of the key molecular targets under investigation to find gaps in the market for your product
View Cart
